Effect of buthionine sulphoximine, glutathione and methimazole on the renal disposition of cisplatin and on cisplatin-induced nephrotoxicity in rats: Pharmacokinetic-toxicodynamic analysis

Journal of Pharmacy and Pharmacology

Volumn 52, Issue 12, 2000, Pages 1483-1490

  Hanada, K ^a   Mukasa, Y ^a   Nomizo, Y ^a   Ogata, H ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; CISPLATIN; GLUTATHIONE; THIAMAZOLE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; DRUG UPTAKE; DRUG URINE LEVEL; KIDNEY PARENCHYMA; LIVER PARENCHYMA; MALE; NEPHROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PROTECTION; RAT; TISSUE LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BLOOD UREA NITROGEN; BUTHIONINE SULFOXIMINE; CISPLATIN; GLOMERULAR FILTRATION RATE; GLUTATHIONE; KIDNEY; KIDNEY CORTEX; KIDNEY DISEASES; MALE; METHIMAZOLE; RATS; RATS, WISTAR; TEMPERATURE; TIME FACTORS;

EID: 0034533775     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357001777694     Document Type: Article

References (26)

1. Cisplatin Metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin
2. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II)
3. Cisplatin pharmacokinetics: Applications of a physiological model
4. Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat
5. Increases in urinary enzyme excretion in rats depleted of glutathione inhibited by scavenger of oxygen free radicals
6. Quantitative determination of unchanged cisplatin in rat kidney and liver by high-performance liquid chromatography
7. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats
8. Uptake of cisplatin and its metabolites into rat and rabbit renal cortical slices
9. Enhancement of cisplatin toxicity by buthionine sulfoximine, a glutathione-depleting agent, in mice
10. Mechanism of cis-platinum nephrotoxicity (Effects of sulfhydryl groups in rat kidneys)
11. The role of glutathione and metallothionein in the toxicity and subcellular binding of cisplatin
12. Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor
13. Glutathione, ascorbate, and cellular protection
14. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats
15. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats - Importance of area under the concentration-time curve (AUC) as the major toxicodynamic determination in vivo
16. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: Protective mechanism against cisplatin nephrotoxicity
17. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients
18. Uptake and metabolism of cisplatin by rat kidney
19. Methimazole protection of rats against chemically induced kidney damage in vivo
20. Essential disulfide and sulfhydryl groups for organic cation transport in renal brush-border membranes
21. Program NLS
22. Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model
23. Determination of insulin in plasma and urine by use of anthrone
24. Effects of sodium thiosulfate on the pharmacokinetics of total platinum after intravenous administration of cisplatin to rabbits
25. Protective effect of reduced glutathione against cisdichlorodiammine platinum (II) - Induced nephrotoxicity and lethal toxicity
26. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug